Literature DB >> 33846499

Eotaxin-1/CCL11 is involved in cell migration in rheumatoid arthritis.

Kuninobu Wakabayashi1, Takeo Isozaki2, Yumi Tsubokura2, Sayaka Fukuse2, Tsuyoshi Kasama2.   

Abstract

Eotaxin-1 (CCL11) induces the migration of different leukocyte types by interacting with CCR3. In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) are pathogenic effectors and a major CCR3-expressing cell. The aim of this study was to investigate the expression and function of CCL11 in RA FLS. The expression of CCL11 and CCR3 was evaluated by ELISA, immunofluorescence and quantitative PCR analysis. The CCL11 levels in serum and synovial fluids (SFs) from RA patients were significantly higher than those in serum from healthy controls and SFs from osteoarthritis patients. CCL11 and CCR3 were expressed in the RA synovial tissue lining layers. The secretion of CCL11 in RA FLS-conditioned medium and the mRNA expression of CCL11 and CCR3 were induced by TNF-α. Furthermore, CCL11 induced the mRNA expression of CCL11 and CCR3. Application of a CCR3 antagonist reduced TNF-α-induced CCL11 secretion from RA FLS. CCL11 induced the migration of RA FLS and monocytes. RA FLS migration was decreased by treatment with CCL11 siRNA. The migration of monocytes to medium conditioned with CCL11 siRNA-transfected and TNF-α-stimulated RA FLS was reduced. These data indicate that the self-amplification of CCL11 via CCR3 may play an important role in cell migration in RA.

Entities:  

Year:  2021        PMID: 33846499     DOI: 10.1038/s41598-021-87199-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  22 in total

Review 1.  The MCP/eotaxin subfamily of CC chemokines.

Authors:  E Van Coillie; J Van Damme; G Opdenakker
Journal:  Cytokine Growth Factor Rev       Date:  1999-03       Impact factor: 7.638

Review 2.  The pathogenesis of rheumatoid arthritis.

Authors:  Iain B McInnes; Georg Schett
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

3.  Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3.

Authors:  M Kitaura; T Nakajima; T Imai; S Harada; C Combadiere; H L Tiffany; P M Murphy; O Yoshie
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

Review 4.  Pathogenic stromal cells as therapeutic targets in joint inflammation.

Authors:  Stephanie G Dakin; Mark Coles; Jonathan P Sherlock; Fiona Powrie; Andrew J Carr; Christopher D Buckley
Journal:  Nat Rev Rheumatol       Date:  2018-12       Impact factor: 20.543

Review 5.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors.

Authors:  Nunzio Bottini; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

6.  Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression, and identification of eotaxin sequence variants.

Authors:  J Bartels; C Schlüter; E Richter; N Noso; R Kulke; E Christophers; J M Schröder
Journal:  Biochem Biophys Res Commun       Date:  1996-08-23       Impact factor: 3.575

7.  Dermal fibroblasts represent a potent major source of human eotaxin: In vitro production and cytokine-mediated regulation.

Authors:  M Miyamasu; T Nakajima; Y Misaki; S Izumi; N Tsuno; T Kasahara; K Yamamoto; Y Morita; K Hirai
Journal:  Cytokine       Date:  1999-10       Impact factor: 3.861

Review 8.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

9.  Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids.

Authors:  C M Lilly; H Nakamura; H Kesselman; C Nagler-Anderson; K Asano; E A Garcia-Zepeda; M E Rothenberg; J M Drazen; A D Luster
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

10.  Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal.

Authors:  Mattias N D Svensson; Martina Zoccheddu; Shen Yang; Gyrid Nygaard; Christian Secchi; Karen M Doody; Kamil Slowikowski; Fumitaka Mizoguchi; Frances Humby; Rebecca Hands; Eugenio Santelli; Cristiano Sacchetti; Kuninobu Wakabayashi; Dennis J Wu; Christopher Barback; Rizi Ai; Wei Wang; Gary P Sims; Piotr Mydel; Tsuyoshi Kasama; David L Boyle; Francesco Galimi; David Vera; Michel L Tremblay; Soumya Raychaudhuri; Michael B Brenner; Gary S Firestein; Costantino Pitzalis; Anna-Karin H Ekwall; Stephanie M Stanford; Nunzio Bottini
Journal:  Sci Adv       Date:  2020-06-26       Impact factor: 14.136

View more
  4 in total

1.  Identification of Robust Biomarkers for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With House Dust Mite-Induced Allergic Rhinitis by Multiple Cytokine Profiling.

Authors:  Shaobing Xie; Ruohao Fan; Qingping Tang; Xiao Cai; Hua Zhang; Fengjun Wang; Shumin Xie; Kelei Gao; Junyi Zhang; Zhihai Xie; Weihong Jiang
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

2.  Cytokines and chemokines multiplex analysis in patients with low disease activity rheumatoid arthritis.

Authors:  Maria Skrzypkowska; Mariusz Stasiak; Justyna Sakowska; Joanna Chmiel; Agata Maciejewska; Adam Buciński; Bartosz Słomiński; Piotr Trzonkowski; Piotr Łuczkiewicz
Journal:  Rheumatol Int       Date:  2022-02-18       Impact factor: 2.631

Review 3.  G-Protein-Coupled Receptors in Rheumatoid Arthritis: Recent Insights into Mechanisms and Functional Roles.

Authors:  Jianan Zhao; Kai Wei; Ping Jiang; Cen Chang; Lingxia Xu; Linshuai Xu; Yiming Shi; Shicheng Guo; Dongyi He
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 4.  Small interfering RNAs in the management of human rheumatoid arthritis.

Authors:  Giuseppe Gargano; Francesco Oliva; Antonio Oliviero; Nicola Maffulli
Journal:  Br Med Bull       Date:  2022-07-09       Impact factor: 5.841

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.